The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this study, we investigated the impact of mutations on BRCA1 isoform expression and th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Wang, Yifan, Bernhardy, Andrea J., Cruz, Cristina, Krais, John J., Nacson, Joseph, Nicolas, Emmanuelle, Peri, Suraj, van der Gulden, Hanneke, van der Heijden, Ingrid, O'Brien, Shane W., Zhang, Yong, Harrell, Maribel I., Johnson, Shawn F., Candido Dos Reis, Francisco J., Pharoah, Paul D. P., Karlan, Beth, Gourley, Charlie, Lambrechts, Diether, Chenevix-Trench, Georgia, Olsson, Håkan, Benitez, Javier J., Greene, Mark H., Gore, Martin, Nussbaum, Robert, Sadetzki, Siegal, Gayther, Simon A., Kjaer, Susanne K., D'Andrea, Alan D., Shapiro, Geoffrey I., Wiest, David L., Connolly, Denise C., Daly, Mary B., Swisher, Elizabeth M., Bouwman, Peter, Jonkers, Jos, Balmaña, Judith, Serra, Violeta, Johnson, Neil
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874568/
https://ncbi.nlm.nih.gov/pubmed/27197267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0186
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares